Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Schrödinger (SDGR)

Schrödinger Q3 revenue rises 19% to $64.5 million; raises 2026 ACV and drug discovery guidance

Mixed Impact 4 of 5 earnings

Schrödinger reported third-quarter 2026 total revenue of $64.5 million, up 19%, and raised its full-year 2026 ACV and drug discovery revenue guidance. The net loss widened to $37.7 million from $32.8 million, and the company corrected a American Society of Hematology abstract that wrongly described an ongoing SGR-1505 combination study. Shareholders see a higher top line and outlook alongside a larger loss.

Key points

  • Total revenue was $64.5 million, up from $54.3 million, with drug discovery revenue of $24.2 million helped by a Structure Therapeutics milestone payment.
  • Net loss was $37.7 million, or $0.50 per share, compared with a net loss of $32.8 million, or $0.45 per share, a year earlier.
  • 2026 ACV guidance was raised to $222 million to $232 million, and drug discovery revenue guidance to $75 million to $85 million.
  • The company said it has not started a combination study of SGR-1505 under its FDA-cleared protocol and is exploring strategic opportunities for the program.

The filing

CompanySchrödinger (SDGR)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:06 PM ET
Accession number0001490978-26-000075

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 7, 2026, 11:17 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.